Literature DB >> 20392298

Excellent lithium responders have normal cognitive functions and plasma BDNF levels.

Janusz K Rybakowski1, Aleksandra Suwalska.   

Abstract

In bipolar patients, neuropsychological and biochemical disturbances persist into the remission period. Excellent lithium responders (ELRs) comprise around one third of lithium-treated patients and have total remission of recurrences on lithium monotherapy. The objective of the study was to assess the performance on neuropsychological tests and to measure brain-derived neurotrophic factor (BDNF) plasma levels in ELRs compared to patients where the effect of lithium was not optimal, and with matched healthy control subjects. The study was performed with 60 patients on prophylactic lithium treatment, 13 of whom were ELRs, and with 60 matched healthy controls. Neuropsychological tests from the CANTAB battery measuring spatial working memory and sustained attention were used. ELRs performed better on all neuropsychological tests, and had higher plasma BDNF levels than the remaining lithium patients but not different from those of healthy controls. ELRs may constitute a specific subgroup of bipolar patients in which long-term lithium administration can produce complete normality.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20392298     DOI: 10.1017/S1461145710000404

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  26 in total

Review 1.  Does lithium prevent Alzheimer's disease?

Authors:  Orestes V Forlenza; Vanessa J de Paula; Rodrigo Machado-Vieira; Breno S Diniz; Wagner F Gattaz
Journal:  Drugs Aging       Date:  2012-05-01       Impact factor: 3.923

Review 2.  Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders.

Authors:  O V Forlenza; V J R De-Paula; B S O Diniz
Journal:  ACS Chem Neurosci       Date:  2014-05-06       Impact factor: 4.418

Review 3.  Inflammatory mediators of cognitive impairment in bipolar disorder.

Authors:  Isabelle E Bauer; Michaela C Pascoe; Bianca Wollenhaupt-Aguiar; Flavio Kapczinski; Jair C Soares
Journal:  J Psychiatr Res       Date:  2014-05-02       Impact factor: 4.791

Review 4.  Cognitive Impairment in Patients with Bipolar Disorder: Impact of Pharmacological Treatment.

Authors:  Ni Xu; Benjamin Huggon; Kate E A Saunders
Journal:  CNS Drugs       Date:  2020-01       Impact factor: 5.749

Review 5.  Glycogen synthase kinase-3 as a therapeutic target for cognitive dysfunction in neuropsychiatric disorders.

Authors:  Olivia O'Leary; Yvonne Nolan
Journal:  CNS Drugs       Date:  2015-01       Impact factor: 5.749

Review 6.  Kidney, thyroid and other organ functions after 40 years or more of lithium therapy: a case series of five patients.

Authors:  Agnieszka Permoda-Osip; Maria Abramowicz; Agnieszka Kraszewska; Aleksandra Suwalska; Maria Chlopocka-Wozniak; Janusz K Rybakowski
Journal:  Ther Adv Psychopharmacol       Date:  2016-04-17

Review 7.  Lithium's role in neural plasticity and its implications for mood disorders.

Authors:  J D Gray; B S McEwen
Journal:  Acta Psychiatr Scand       Date:  2013-04-26       Impact factor: 6.392

Review 8.  Potential mechanisms of action of lithium in bipolar disorder. Current understanding.

Authors:  Gin S Malhi; Michelle Tanious; Pritha Das; Carissa M Coulston; Michael Berk
Journal:  CNS Drugs       Date:  2013-02       Impact factor: 5.749

Review 9.  Role of lithium augmentation in the management of major depressive disorder.

Authors:  Michael Bauer; Mazda Adli; Roland Ricken; Emanuel Severus; Maximilian Pilhatsch
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

10.  Long-term lithium treatment reduces glucose metabolism in the cerebellum and hippocampus of nondemented older adults: an [¹⁸F]FDG-PET study.

Authors:  Orestes V Forlenza; Artur Martins Novaes Coutinho; Ivan Aprahamian; Silvana Prando; Luciana Lucas Mendes; Breno S Diniz; Wagner F Gattaz; Carlos A Buchpiguel
Journal:  ACS Chem Neurosci       Date:  2014-04-29       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.